TNFRSF18 and cancer: Increasing the Teffector/Treg ratio at the tumor microenvironment by targeting GITR with the mGITRL-FP could be considered an immune adjuvant and, thus, may be an effective approach to enhance the antitumor efficacy of a cancer vaccine.